Theravance Biopharma (NASDAQ:TBPH) Cut to Buy at Wall Street Zen

Wall Street Zen lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.

Other analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. BTIG Research boosted their price objective on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Finally, Oppenheimer began coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $27.80.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $18.42 on Friday. The company’s 50 day simple moving average is $17.72 and its 200 day simple moving average is $14.54. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $20.33. The firm has a market capitalization of $933.34 million, a price-to-earnings ratio of 32.32 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.10. The firm had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. As a group, analysts predict that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the transaction, the senior vice president directly owned 277,695 shares of the company’s stock, valued at $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in TBPH. Assenagon Asset Management S.A. bought a new position in Theravance Biopharma in the 2nd quarter valued at about $264,000. Inspire Investing LLC acquired a new position in shares of Theravance Biopharma in the third quarter valued at approximately $1,074,000. Cubist Systematic Strategies LLC bought a new position in shares of Theravance Biopharma during the first quarter worth approximately $419,000. Acadian Asset Management LLC increased its stake in shares of Theravance Biopharma by 76.8% during the second quarter. Acadian Asset Management LLC now owns 308,652 shares of the biopharmaceutical company’s stock worth $3,401,000 after purchasing an additional 134,058 shares during the period. Finally, Jefferies Financial Group Inc. lifted its holdings in Theravance Biopharma by 1,191.9% during the 2nd quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company’s stock worth $3,054,000 after purchasing an additional 255,455 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.